Eversense® Non-adjunctive Use Post Approval Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

925

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Diabetes
Interventions
DEVICE

Blood glucose meter

First phase: SMBG for 6 months

DEVICE

Eversense CGM System

Second phase: CGM for 6 months

Trial Locations (23)

11101

Endocrine Associates of West Village, Long Island City

20746

Southern Maryland Medical Group, Camp Springs

27577

Superior Clinical Research, Smithfield

27834

Physician's East Endocrinology, Greenville

30318

Atlanta Diabetes Associates, Atlanta

33014

Miami Lakes Clinical Trials INC, Miami Lakes

33165

MedCare Research, Miami

33312

The Center for Diabetes and Endocrine Care, Fort Lauderdale

38133

AM Diabetes & Endocrinology, Bartlett

48126

Metro Detroit Endocrinology, Dearborn

62702

Springfield Clinic, Springfield

63017

Diabetes and Endocinology Specialists, Inc., Chesterfield

70072

Tandem Clinical Research, Marrero

75235

Southwest Family Medicine Associates, Dallas

77095

Clinical Research Solution Institute, Houston

78503

RGV Endocrine Center, McAllen

78749

Texas Diabetes and Endocrinology, Austin

80113

Denver Endocrinology, Diabetes & Thyroid Center, Englewood

83404

Rocky Mountain Clinical Research, Idaho Falls

90057

LA Universal Research Center, Inc., Los Angeles

06517

CMR of Greater New Haven, Hamden

06708

Chase Medical Research, Waterbury

05701

Green Mountain Research Institute, Rutland

All Listed Sponsors
lead

Senseonics, Inc.

INDUSTRY